All In Biotech

Free tool

FAERS Monitor: Infed

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 017441 or its brand name (Infed, Iron Dextran). Reports on generic versions are filed under their own applications.

Reports

1,486

Serious

956

64% of reports

Hospitalization

354

Death reported

124

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea264
  • infusion related reaction167
  • nausea126
  • flushing115
  • anaphylactic reaction112
  • back pain111
  • chest pain102
  • dizziness88
  • chest discomfort85
  • pruritus81
  • off label use80
  • hypotension72
  • vomiting66
  • headache61
  • diarrhoea59

Reports by year received

View as table
YearReports
200445
200549
200648
200746
200843
200939
201036
201139
201260
201326
201417
201534
201645
201747
201868
201960
202061
202199
202291
202392
2024143
2025172
2026126

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,673 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infusion related reactionSignal16735.731.05,609
anaphylactic reactionSignal11228.724.12,974
flushingSignal11516.013.41,611
chest discomfortSignal8511.89.6829
chest painSignal1027.86.5603
back painSignal1116.85.7545
dyspnoeaSignal2646.65.91,284
hypotensionSignal725.14.1234
pruritusSignal813.02.4107
dizzinessSignal882.52.079
nauseaSignal1262.31.990
vomiting662.01.632
headache611.41.16
diarrhoea591.31.04
off label use801.31.05

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.